Vyome Biosciences: FDA Has Accepted IND for Investigational Acne Therapy


The FDA has accepted from Vyome Biosciences an Investigational New Drug (IND) Application for the initiation of clinical studies for its lead program VB 1953, a topical therapeutic candidate for the treatment of moderate-to-severe acne. Vyome plans to start the Phase I clinical trials very soon.

Physicians around the world have cited a large unmet need for new, improved topical therapy options, vis-à-vis the current available topical products. Vyome’s program VB 1953 targets this large unmet need of an effective topical treatment option.

Apart from the lead program VB 1953, Vyome has a deep R&D pipeline of Dual Action Rational Therapeutics (DARTs) antibiotics that are very less prone to resistance development. Vyome also has a portfolio of clinically tested and commercialized products with superior efficacy for various fungal indications, developed using its breakthrough technology platform Molecular Replacement Therapy (MRTTM).

Facebook Comments


We’re glad to see you’re enjoying PracticalDermatology…
but how about a more personalized experience?

Register for free